Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Innovative Medicines for Tuberculosis Foundation (iM4TB)
Street 1: Building I
Street 2: EPFL Innovation Park
City: Lausanne
Post Code: 1015
Country: Switzerland
Phone: +41 21 69 31754
Organization Email:
Web Site:
Other Online Presence:

Focal Point Contact Information

Salutation: Dr
First Name: Iain
Last Name: Old
Title: Chief Operating Officer
Phone: +41 21 69 31754

Alternate Focal Point Contact Information

Salutation: Dr
First Name: Jean-Yves
Last Name: Gillon
Title: Global Project Leader

General Information

Board Constituency: Foundation
Is your organization legally registered in your country: Yes
If yes, please enter your registration number:
Organization Type - Primary: Foundation
Organization Type - Secondary: Charitable / Philanthropic Foundation
Organization Description:
The Innovative Medicines for Tuberculosis (iM4TB) Foundation aims to support, promote and actively participate in drug discovery and drug development concerning Tuberculosis and similar poverty-related and neglected diseases such as leprosy or Buruli ulcer. This includes support and coordination of R+D activities as well as conducting specific studies on identified candidate drugs such as toxicology and early clinical trials.

The most acute need for anti-Tubercular drugs is in those countries that can least afford to pay for medicines. Therefore the development of drugs active against TB and other poverty-related and neglected diseases is difficult to finance through classical private investment due to rather unattractive profit margins in developing countries. Yet these are the very countries that most need effective and affordable anti-Tubercular drugs.

The Foundation will therefore attempt to bridge the gap between the scientific discovery of new potential drugs and the successful completion of Phase I clinical trials. It is expected that after successful Phase I clinical trials, private companies will be interested in bringing the drug candidates through Phases II and III and then on to the market. The Foundation’s aim is to provide affordable medicines where they are most needed.
Do you know about the UNHLM declaration:

Specializations / Areas of Work

Funding, including innovative and optimized approach to funding TB Care
Provision of drugs, diagnostics and commodities
Research and Development

Other Organization Information

Total number of staff in your organization: 1 - 5
Number of full-time staff who are directly involved with TB: 1 - 5
Number of part-time staff who are directly involved with TB: 0
Number of volunteers who are directly involved with TB: 1 - 5
How did you hear about the Stop TB Partnership: Attendance at a TB related event
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Network with other partners
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: No
Please tell us how your organization is contributing to your country's national TB control plan:
Raising money for TB research.
TB drug development.

Geographical Reach

Which country is your headquarters located in: Switzerland
Which countries do you do operate in:
(This includes countries you are conducting activities in)


Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

New TB Drugs:
Our drug candidate, PBTZ169 is in the pipeline.


Declaration of interests:

Application date: February 24, 2014
Last updated: March 11, 2014